Related Experiment Videos
Bone marrow transplantation: current results in leukemia.
The Yale Journal of Biology and Medicine
|September 1, 1982
Summary
Bone marrow transplantation offers intensive leukemia treatment and immunotherapy via graft-versus-host disease (GVHD). Research addresses challenges like GVHD and infections to improve survival rates in leukemia patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Bone marrow transplantation (BMT) presents advantages over conventional leukemia therapy.
- Allogeneic BMT allows intensive treatment and an immunotherapeutic effect via graft-versus-host disease (GVHD).
- Early BMT use in end-stage patients had high mortality, but transplanting in remission improved survival.
Purpose of the Study:
- To review the therapeutic advantages and challenges of bone marrow transplantation in leukemia treatment.
- To highlight advancements in addressing obstacles such as GVHD, viral infections, and relapse.
- To discuss the potential of syngeneic and autologous BMT, including tumor cell purging techniques.
Main Methods:
- Review of existing literature on bone marrow transplantation for leukemia.
- Analysis of outcomes in allogeneic, syngeneic, and autologous BMT approaches.
- Examination of strategies to mitigate BMT-related toxicities and complications.
Main Results:
- Allogeneic BMT in remission significantly improved survival for acute lymphocytic leukemia (ALL) and acute non-lymphocytic leukemia (ANLL).
- Syngeneic BMT shows promise, particularly for chronic myelogenous leukemia (CML).
- Pharmacologic and immunologic purging techniques are being developed to address marrow contamination in autologous BMT.
Conclusions:
- Bone marrow transplantation is a valuable therapeutic option for leukemia, with ongoing research addressing key challenges.
- Improvements in managing GVHD, infections, and relapse are crucial for further enhancing BMT efficacy.
- Autologous BMT, with effective tumor cell purging, holds significant future potential.